Business Wire

New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection

Share

iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand new “SCREEN-AF” study, led by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada and University Hospital in Leipzig, Germany, which was published in JAMA Cardiology.

The transatlantic clinical trial found that Zio by iRhythm, an ambulatory cardiac monitoring solution, led to a tenfold increase in the detection of atrial fibrillation (AF) versus patients receiving standard clinical care. One out of every 20 patients in the heart monitoring group was found to have a new diagnosis of atrial fibrillation and, as a result, 75 percent of those patients were subsequently prescribed a blood thinner medication for protection against strokes.

The study results lend support for Zio as a screening tool for early detection of AF. The results have important implications for stroke prevention, especially as the prevalence of AF and AF-associated strokes is increasing with the aging of the population. Zio was found to be well tolerated and effective, and the results enabled some patients to receive anticoagulant therapy (anti-clotting medication) which has the potential to avert future strokes.

“Approximately one-third of those who have AF are not aware that they have it, leaving them at a significantly elevated risk of stroke,” said Michael Coyle, CEO at iRhythm. “The clinical validation that iRhythm has seen through its recent trials – mSToPS and SCREEN-AF – demonstrates that Zio proactively identifies arrhythmias based on risk factors, helping undiagnosed populations remotely monitor their symptoms and effectively seek treatment before more serious problems can occur.”

Unlike handheld ECGs, watches, and blood pressure monitors, wearable continuous ECG devices can serve as both a screening tool and a diagnostic test, likely reducing the need for confirmatory testing. When compared with implanted cardiac monitors, wearable ECG devices are noninvasive, less costly, more accessible, and can be self-applied by patients at home.

Commenting on the news, Justin Hall, GM and VP EMEA at iRhythm said, “AF is currently the leading independent risk factor of stroke, with more than 886,000 new people being diagnosed across Europe each year. As with many heart conditions, the key to improving the outcome of AF – and therefore the associated risk of stroke – is through earlier and more accurate detection. The sooner an individual is diagnosed; the sooner medical practitioners can deploy the best course of treatment. This is something that Zio can help to achieve, even during the ongoing pandemic, through accurate, remote monitoring.”

“The big challenge is that atrial fibrillation is often a silent risk factor that can be difficult to detect with current methods,” says Dr. David Gladstone, the study’s principal investigator and stroke neurologist from Sunnybrook Health Sciences Centre and Department of Medicine in the University of Toronto Temerty Faculty of Medicine. “If we are able to better detect atrial fibrillation, then more people could receive treatment for it earlier, and more strokes ought to be prevented,” adds Dr. Gladstone, who recently presented the research findings at the World Stroke Congress.

“These results are an important step towards stroke prevention by early detection of atrial fibrillation,” said Dr. Rolf Wachter, co-principal investigator, cardiologist at the University Hospital in Leipzig, Germany and scientist at the German Center for Cardiovascular Research.

In recent months, iRhythm has also been awarded a positive recommendation from the National Institute for Health and Care Excellence (NICE), as well as being named a winner of the UK government’s AI in Health and Care Award. Both achievements – along with this most recent study – are opening the door for the Zio service to be more widely adopted within the NHS.

About the study

The study recruited 856 individuals from 48 primary care clinics between 2015 and 2019. It involved participants aged 75 years or older who had high blood pressure but no previous diagnosis of AF. Half of the participants were given Zio monitors to wear at home for up to four weeks, while the other half of participants received standard medical care. All participants were observed for six months.

Clinical collaboration was supported through Sunnybrook Health Sciences Centre, the German Center for Cardiovascular Research, the Heart Center in Göttingen, and the Population Health Research Institute.

Read the full study here.

About Atrial Fibrillation
Atrial fibrillation (AF or AFib) is a quivering or irregular heartbeat, also known as an arrhythmia, which can lead to blood clots, stroke, heart failure, and other heart-related complications. Normally, the heart contracts and relaxes to a regular beat. In AF, the upper chambers of the heart (the atria) beat irregularly instead of beating effectively to move blood into the ventricles.
AF is associated with up to a five-fold increase1 in the risk of stroke, with these strokes tending to be severe and often associated with high mortality. However, approximately one-third2 of those who have AF are not aware that they have it.

For many individuals who experience a stroke due to AF, the occurrence of AF was not diagnosed until the time of their stroke or shortly afterward. Asymptomatic or undiagnosed AF is referred to as being “silent” and there are certain risk factors like aging and high blood pressure that increase an individual’s likelihood of developing it.

About the SCREEN-AF Study
SCREEN-AF was an investigator-initiated and investigator-led academic clinical trial that evaluated home-based atrial fibrillation screening in older primary care patients with hypertension. A wearable cECG strategy for up to four weeks detected a substantial prevalence (5%) of subclinical AF, was superior to six months of standard clinical care for AF detection, and resulted in more patients prescribed anticoagulant medication for stroke prevention. Most AF cases were paroxysmal, with episodes lasting many hours. Patient adherence to cECG was high; three-quarters of AF cases were detected within the first two weeks of ECG monitoring, and 90% of cases would have been missed using a 24-hour Holter monitor alone.

ClinicalTrials.gov Identifier: NCT02392754

About iRhythm Technologies, Inc.
iRhythm is a leading digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterisation have the potential to change the clinical management of patients.


1lf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.
2iberg L, Rosenqvist M, Lindgren A, Terént A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605.

Contact information

Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investors@irhythmtech.com

Media Contact:
Saige Smith
(262) 289-7065
irhythm@highwirepr.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BIO KOREA 2021 International Convention Is Ready - Showing What Makes Korea’s Bio-health Market at Record High20.4.2021 14:00:00 CEST | Press release

The 16th edition of BIO KOREA, the reference B2B event for global biotech and health industry professionals interested in opportunities in the Asian region, will be held online from 9th to 21st June 2021 with an onsite show at COEX in Seoul from 9th to 11th June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005089/en/ In the global market, the bio-health industry is notching an annual average growth rate of 4 percent, higher than the shipbuilding and auto-making industry at 2.9 percent and at 1.5 percent, respectively. Especially, the Korean bio-health industry shows remarkable growth – its bio-health industry set a new milestone in outbound shipments with a 50 percent jump last year, led by robust demand for COVID-19 test kits and biosimilar products. With the record high export figures, the bio-health sector joins the ranks of the mainstay export industry for the first time in its history. The game-changers of the

Munich Re’s Consulting Unit Boosts Its Pricing Capabilities With Akur8 in Global Cooperation20.4.2021 14:00:00 CEST | Press release

Akur8 is delighted to announce their global cooperation agreement with Munich Re to boost Munich Re’s pricing capabilities for their Global Consulting Unit1. With this agreement, Munich Re will have access to a new state-of-the-art rate modelling solution and Akur8 will reinforce its footprint by partnering with one of the world’s leading providers of insurance, reinsurance and insurance-related risk solutions. This non-exclusive cooperation is global, with users in multiple Munich Re operating geographies. All Munich Re entities and clients can benefit from the joint approach and tap into this solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005018/en/ Specifically developed for insurance, Akur8’s solution enhances insurers’ pricing processes by automating risk and demand modelling, using transparent Artificial Intelligence proprietary technology. The core benefits for insurers include a reduction in modelling

Woolworths Group Selects One Door to Improve the Store Team Experience20.4.2021 14:00:00 CEST | Press release

One Door, Inc., the leading provider of cloud-based visual merchandising software, today announced a new multi-year agreement with the Woolworths Group. Woolworths will implement One Door’s Merchandising Cloud platform across its supermarkets to simplify and streamline work for its in-store merchandising teams. “We are thrilled to partner with Woolworths to have a positive impact on the lives of their customers and team,” said Tom Erskine, CEO of One Door. “Woolworths is a proven retail innovator and we both believe we are only just beginning to jointly understand how these technologies can ultimately improve the work experience for store teams and improve the overall customer experience.” “We’re pleased to partner with One Door to roll out Merchandising Cloud for the benefit of our teams and customers,” said Doug Frank, Woolworths General Manager Group Data & Analytics. “One Door allows us to simplify a critical and time intensive task - making life easier for in-store merchandisers a

Globality Recognized as HFS Hot Vendor by HFS Research20.4.2021 14:00:00 CEST | Press release

Globality, the technology company behind the leading AI-powered digital Platform for sourcing complex, enterprise services, has been recognized as an HFS Hot Vendor by HFS Research, the leading analyst advisory authority covering global IT services, emerging technologies and business operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005687/en/ (Graphic: Business Wire) In the HFS Hot Vendor Report Q1 2021, HFS commends Globality for having “an innovative solution for smart self-sourcing utilizing the combination of automation, AI, and analytics,” while noting that “early mover advantage in the self-service procurement space provides a competitive advantage.” As the report highlights: “With Globality’s sourcing platform, enterprises can embark on intelligent self-service procurement that helps them understand the risks of what they buy, effectively collaborating with stakeholders during the sourcing process, ide

Anari AI Raises $2M to Rebuild the AI Hardware Industry Through Personalized Cloud Chips20.4.2021 13:59:00 CEST | Press release

Anari AI, an AI chip factory in the cloud, today announced it has raised $2 million in seed funding led by Earlybird, with participation from Acequia Capital, Serbian Entrepreneurs, and Eric Ries, author and founder of The Lean Startup. The new funding will be used to continue developing the platform and bring it to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005700/en/ Anari AI: Hardware as code (Photo: Business Wire) Anari’s platform makes it possible to design personalized AI chips in the cloud with just one click. With this approach, companies are able to build and deploy AI solutions in weeks instead of 12-18 months, and at a fraction of the cost of traditional hardware development. “AI continues to be growing in size and complexity, and this rate of growth is outpacing standard CPU and GPU performance gains,” said Roland Manger, co-founder and Partner at Earlybird. “Dedicated designs or flexible archit

New gPROMS Process – Process Modelling and Optimization for the Digital World20.4.2021 13:47:00 CEST | Press release

Process Systems Enterprise (PSE), a Siemens business, today released its rebranded gPROMS Process advanced process modelling environment. Formerly known as gPROMS ProcessBuilder, gPROMS Process 2.0 is the first major release since PSE was acquired by Siemens. Eckard Eberle, CEO of Siemens Digital Industries Process Automation division, says “the significantly enhanced capabilities and functionality you see in this release reflect the substantial investment Siemens is making into product development within PSE to provide the process industries with a new generation of digital tools.” Costas Pantelides, PSE CEO and architect of the gPROMS platform, says “The name change signifies a break with the past. Until now, ProcessBuilder has been an environment for sophisticated users who are typically running high-value, complex optimizations. This is the first release in a major, multi-year development programme that will bring the cutting-edge capabilities of the gPROMS platform to users across

Velodyne Lidar Signs Multi-Year Sales Agreement with Gatik20.4.2021 12:48:00 CEST | Press release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced a multi-year sales agreement with Gatik, the industry leader in automating on-road transportation networks for B2B middle mile logistics. Gatik uses Velodyne’s lidar sensors as a key part of a fully redundant sensor suite to deliver goods safely and efficiently between micro-fulfilment centers, dark stores and retail locations – a logistics flow known as the middle mile. Gatik fulfills revenue-generating autonomous orders daily for multiple Fortune 500 customers in the US and Canada, including Walmart, reducing customer costs and keeping delivery times short. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005317/en/ Velodyne Lidar announced a multi-year sales agreement with Gatik, industry leader in automating on-road transportation networks for B2B middle mile logistics. Gatik uses Velodyne’s lidar sensors to support short-haul logistics with precise, reliable

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom